Unknown

Dataset Information

0

Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2.


ABSTRACT:

Background

Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines.

Main body

We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class 5 months earlier on average. After controlling for the time since vaccination, Spike-binding antibody and neutralizing antibody levels were higher in the mRNA-vaccinated subjects, while no significant differences in antigen-specific B cell and T cell responses were observed between the two groups.

Conclusions

A dichotomy exists between the humoral and cellular responses elicited by the two vaccine classes. Testing only for humoral responses to compare the durability of SARS-CoV-2 vaccine-induced responses, as typically performed for public health and research purposes, is insufficient.

SUBMITTER: Ukey R 

PROVIDER: S-EPMC8786593 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2.

Ukey Rahul R   Bruiners Natalie N   Mishra Hridesh H   Mishra Pankaj K PK   McCloskey Deborah D   Onyuka Alberta A   Chen Fei F   Pinter Abraham A   Weiskopf Daniela D   Sette Alessandro A   Roy Jason J   Gaur Sunanda S   Gennaro Maria Laura ML  

BMC medicine 20220125 1


<h4>Background</h4>Protection from severe disease and hospitalization by SARS-CoV-2 vaccination has been amply demonstrated by real-world data. However, the rapidly evolving pandemic raises new concerns. One pertains efficacy of adenoviral vector-based vaccines, particularly the single-dose Ad26.COV2.S, relative to mRNA vaccines.<h4>Main body</h4>We investigated the immunogenicity of Ad26.COV2.S and mRNA vaccines in 33 subjects vaccinated with either vaccine class 5 months earlier on average. Af  ...[more]

Similar Datasets

| S-EPMC8475964 | biostudies-literature
| S-EPMC8957851 | biostudies-literature
| S-EPMC9431224 | biostudies-literature
| S-EPMC10982398 | biostudies-literature
| S-EPMC10535273 | biostudies-literature
| S-EPMC8575273 | biostudies-literature
| S-EPMC9312914 | biostudies-literature
| S-EPMC9963157 | biostudies-literature
| S-EPMC10475480 | biostudies-literature
| S-EPMC10897323 | biostudies-literature